genin, and formononetin, present in C. intermedia [5, 15] . Recent investigations demonstrated the presence of benzophenones and dihydrochalcones in C. subternata [15, 17] . An iriflophenone-di-O,C-hexoside, an eriodictyol-di-C-hexoside, 3-hydroxyphloretin-3,5-di-C-hexoside, and vicenin-2 (apigenin-6,8-di-C-glucoside) were tentatively identified in C. subternata, based on UV-Vis, LC-MS, and LC-MS/MS characteristics of the compounds [17] . l " Fig. 2 depicts phenolic compounds present in C. subternata. The abundance of C-glycosides, both in terms of content and number of compounds (l " Fig. 1 , Table 1 ), has implications concerning stability during processing and in vivo. The C-C bond is very stable and resistant to acid and intestinal enzymes able to hydrolyse O-glycosides, but evidence of C-C bond-cleaving reactions by human intestinal bacteria is growing [18] [19] [20] . Relatively high levels of certain phenolic compounds are present in the leaves of C. subternata (l " Table 1 ). These values could vary substantially as recently demonstrated by De Beer et al. [17] for seedling plants. Several of the compounds, including mangiferin, isomangiferin, iriflophenone-3-C-glucoside, scolymoside, the 7-O-rutinoside of luteolin, and eriocitrin, the 7-O-rutinoside of eriodictyol, occur in higher levels in aqueous extracts prepared from the leaves, while hesperidin, the 7-O-rutinoside of hesperetin, and the dihydrochalcone C-glycosides are predominant in the stems. Although natural variation is a contributing factor, trace or undetectable quantities of luteolin by HPLC-DAD in aqueous extracts, whilst present in the methanol extract (l " Table 1) , are attributed to poor solubility of this aglycone in water.
Phytoestrogenic Potential of Cyclopia Polyphenols and Extracts ! Phytoestrogenic potential may be defined in terms of the mechanism of action of the endogenous hormone 17β-estradiol (E 2 ) [21] . According to this definition, compounds with phytoestrogenic potential would act through at least one of the main isoforms of the estrogen receptor (ER), namely ERα or ERβ [22] , and act as agonists, antagonists, or selective ER modulators (SERMS) via ER signalling pathways [21] (l " Fig. 3 ). Phytoestrogens are, however, also considered to be endocrine disruptors and as such the definition used by regulatory bodies in both the USA and Europe could be useful [23, 24] . The European Commission State of the Art Assessment of Endocrine Disruptors, for example, defines estrogenicity in terms of "binding to the estrogen receptor(s) (ER), ER activation, cell proliferation in ER-competent cells and physiological responses (proliferation of uterine tissue in rodents, induction of vitellogenin in fish)" [24] . Although several assays have been suggested to evaluate estrogenic activity [25] , for the purposes of this review we will evaluate the phytoestrogenic potential of both the polyphenols shown to be present in Cyclopia and extracts prepared from Cyclopia in terms of their in vitro ability to either bind to ERα or ERβ, to induce or prevent activation of ER-responsive promoters, or to cause cell proliferation in ER-responsive cells (e.g., E-screen in MCF-7 cells, a breast cancer cell line) or in terms of their in vivo responses in known estrogenic tissues such as the uterus (l " Fig. 3 , Tables 2, 3 , and 4). In addition, where it was not apparent that the ER was involved, we used evidence of loss of activity via ICI 182,782, an ER antagonist, as confirmation of ER involvement. Although in vivo studies have been considered the "gold standard" for the evaluation of estrogenicity, many authors have not conducted such studies, and thus we have to rely on in vitro results. In terms of in vitro results, it is important to establish that Table 1 Phenolic composition of leaves and extracts (g · 100 g −1 dry basis) of unfermented Cyclopia subternata.
Compound
Leaves [92] (n = 6)
Aqueous extract [16] (n = 6)
Aqueous extract [17] (n = 64)
Methanol extract [44] (n = 1) a hierarchy in terms of sensitivity has been established, with the E-screen generally considered the most sensitive assay [26] [27] [28] . Furthermore, although binding to the ER may be considered a prerequisite for estrogenic activity and is certainly the most characteristic mode of action of phytoestrogens [29] , receptor binding assays cannot distinguish agonists from antagonists or SERMs [26] . Assays relying on the activation of ER-responsive promoters (both of artificial ERE-containing promoter reporters and endog-enous ERE-containing estrogen responsive genes) and the Escreen are more appropriate assays to distinguish agonists from antagonists and SERMs [26] . Furthermore, to distinguish activation of ERα from activation via ERβ, cell lines expressing these receptors separately have to be utilised. MCF-7 cells, used in the Escreen, contain both ERα and ERβ and thus lack the ability to discriminate between the roles of the ER isoforms [25] . In addition, the uterotrophic assay is primarily an assay to verify ERα-mediat- ed in vivo effects, and no appropriate in vivo assay for ERβ has been established [25] . Initially, we wanted to standardise our comparison of the estrogenic potential of polyphenols in Cyclopia using the relative binding affinity (RBA) and relative induction index (RII) where binding and activation are expressed relative to the values for E 2 (calculated as follows: 100 × IC 50 or EC 50 (E 2 )/IC 50 or EC 50 (test compound), however, we found that few papers provide quantitative data. Thus most of our comparisons of estrogenic activity of the polyphenols present in Cyclopia (l " Table 3 ) rest on qualitative and not quantitative data.
Most of the polyphenols present in Cyclopia have, to our knowledge, not been tested for estrogenicity (l " Table 2 ). For example, the dihydrochalcone phloretin-3′,5′-di-C-β-glucoside, the flavone scolymoside, and the benzophenone iriflophenone-3-C-βglucoside, all present in relatively high concentrations in C. subternata (l " Table 1 ), have not been tested (l " Table 2 ). l " Table 3 summarises data for compounds that have been tested for estrogenicity in different assay systems. Mangiferin, the major xanthone in Cyclopia species (l " Table 1), has been shown to have no estrogenic activity both via ER binding assays and ERE-promoter reporter assays (l " Table 3 ). Although isomangiferin has not been tested (l " Table 2 ), it is unlikely to have estrogenic activity as it is a regioisomer of mangiferin (l " Fig. 2 ). The phenolic acid p-coumaric acid and the coumestan medicagol have both been tested but found not to be estrogenic (l " Table 3 ).
Of the flavanones present in Cyclopia, most have been tested for estrogenicity. Prunin (naringenin-7-O-glucoside), one of the rarer flavanones, is estrogenic, while of the glycosylated flavanones present in relatively high concentrations in Cyclopia (l " Table 1), like eriocitrin and hesperidin, only eriocitrin is estrogenic (l " Table 3 ). Eriodictyol and naringenin, as well as their rutinosyl derivatives, eriocitrin and narirutin bind to ER, although therutinosyl derivatives bind with a lower affinity than their corresponding aglycones. Specifically, in a competitive binding assay, eriodictyol and naringenin displaced 44 % and 70% of 1 nM tritiated E 2 from ERβ, respectively, while their corresponding rutinosyl derivatives displaced 28 % and 28%, respectively [30] . Naringe-nin is interesting as it has been shown to be estrogenic in vitro using the usual array of screening assays, namely ER-binding, activation of ERE-responsive promoters both in promoter reporter studies and with endogenous genes, yet in vivo, using the immature uterotrophic assay, it does not display estrogenicity (l " Table  3 ). This may suggest that naringenin is not absorbed or is inactivated, either during hepatic metabolism or by gut bacteria, and highlights the importance of validating these parameters [31] .
On the other hand, it may also suggest that naringenin does not transactivate via ERα, the ER responsible for uterotrophic action, but rather via ERβ, as borne out by some [32] , but not by other [33] [34] [35] promoter reporter studies. Hesperetin and its rutinosyl derivative, hesperidin, do not bind ER, although hesperetin, but not hesperidin, does transactivate an ERE-containing promoter reporter, which can probably be ascribed to the lower activity of glycosalyted derivatives relative to their aglycones. Furthermore, hesperetin activates estrogen responsive genes and causes cell proliferation in the E-screen via an ER-mediated mechanism as ICI 182,782 antagonises the response. This suggests that the ERbinding assay may not be sensitive enough to evaluate weak estrogenicity, which is further borne out by the fact that in three studies where naringenin and hesperetin were directly compared, hesperetin was a weaker agonist [33, 34, 36] . Specifically, Breinholt and Larsen [36] report EC 50 values of 89.6 µM and 0.3 µM, while Promberger et al. [34] report 2 % and 80 % efficacy for hesperetin and naringenin, respectively, in ERE-containing promoter reporter studies. Liu et al. [33] also clearly show that hesperetin is weaker than naringenin at causing both cell proliferation in the E-screen and activation in promoter reporter studies. The lower activity of hesperetin relative to naringenin may be ascribed to the methyl functional group found on the B-ring of hesperetin (l " Fig. 2 ). The flavanol (−)-epigallocatechin gallate, however, was found to be estrogenic by binding to ER and via the GAL4 promoter assay (a very artificial system in which the ER is fused to a GAL4 element), but not via the ERE-containing promoter reporter assay (l " Table 3 ). This suggests that, contrary to what we have suggested for hesperetin, namely that ER binding may not be sensitive enough to test for weak estrogenic activ- 1) Binding of an estrogenic ligand to the ER may be evaluated by ligand-binding assays, (2) binding of ligand-activated ER to an ERE in the promoter of an estrogen responsive gene may be evaluated by promoter-reporter studies using an ERE-containing promoter reporter or by measuring mRNA levels of select ER-responsive genes, and (3) downstream biological effects such as cell proliferation or hypertrophy of the uterus may be measured using the E-screen or uterotrophic assay, respectively. Table 3 Phytoestrogenic potential of polyphenols found [5] [6] [7] 15] continued ity, some compounds may bind ER but not display estrogenicity in other assays.
Class of compound Specific compound(s)
Of the flavones present in Cyclopia only two, luteolin and diosmetin, have been tested for estrogenicity, and both are estrogenic (l " Table 3 ). Luteolin is present in a methanol extract from C. subternata (l " Table 1 ) and has been shown to be estrogenic via ERbinding, ERE-containing promoter assays, and estrogen responsive genes, as well as by stimulating cell proliferation in the Escreen. It has, however, not been tested in vivo. Work from our laboratory suggests that luteolin binds preferentially to ERβ, with an RBA of 0.52 % for ERβ, while for ERα the RBA is 0.0025 % [30, 32] and that it has a similar affinity for ERβ as naringenin [30, 32, 37] . In promoter reporter assays, luteolin has a lower potency but higher efficacy via ERβ than naringenin, specifically it has a potency of 3.53 × 10 −3 mg/mL (12.3 µM) versus the potency of 1.04 × 10 −4 mg/mL (0.0382 µM) of naringenin and a efficacy of 3.69-fold versus a 2.99-fold induction by naringenin. However, unlike naringenin it does transactivate via ERα, with a potency of 1.97 × 10 −3 mg/mL (6.88 µM), which is just slightly higher than via ERβ. Yet, in the E-screen, it has a lower potency (2.54 × 10 −6 mg/ml or 0.00887 µM) than naringenin (3.27 × 10 −8 mg/ml or 0.00012 µM) suggesting that in terms of a biological response in physiologically relevant tissues, it may favour ERβ. Although the isoflavones shown to be present in Cyclopia are not observed in quantifiable amounts (l " Fig. 2 , Table 1 ), many of them are estrogenic (l " Table 3 ). Of these, formononetin and calycosin have been thoroughly tested, both in vitro and in vivo, and generally show a slight preference for ERβ in ER binding assays [30, 32, 38, 39] . These compounds differ only on the B-ring in that calycosin has a 3′-OH moiety. In promoter reporter studies, the ER isoform preference for formononetin is not so clear [32, 40] , while both compounds are uterotrophic, with calycosin being more potent than formononetin [41, 42] , suggesting that both must act via ERα. Here again we observe the phenomenon of the glycoside being less estrogenic than its corresponding aglycone, with calycosin showing greater estrogenic activity via a promoter reporter construct in MCF-7 cells than calycosin-7-O-glucoside [43] . Orobol, with OH groups at the 3′ and 4′ positions, and ononin, the 7-O-glucoside of formonentin, are also both estrogenic but here their activity appears to be similar to that of calycosin-7-O-glucoside and not to be preferentially via ERβ (l " Table 3 ).
The presence of polyphenols with phytoestrogenic capabilities in the plant material of Cyclopia species (l " Table 3 ) raised the question of whether extracts from the plant material will have phytoestrogenic capabilities. One cannot simply assume that the estrogenicity of the pure compounds will be transferred to extracts of the plant material as varying levels of polyphenols, as well as the presence of various polyphenols with varying levels of estrogenicity, might modulate the effects observed with pure polyphenols. To address this issue, examination of the phytoestrogenicity of crude extracts prepared from the plant material of various commercially cultivated Cyclopia species [30, 32, 44] as well as the HPLC analyses of these extracts to identify the polyphenols present is warranted. We chose two extracts for discussion (l " Table 4), P104 (methanol extract) from C. genistoides as it was found to have the highest binding affinity for both the ER subtypes [32] , and SM6Met (methanol extract of plant material following extraction with ethyl acetate and ethanol) from C. subternata as it had the highest potency when compared to other extracts [44] . P104 bound to both ERα and ERβ, albeit with a lower potency than that of E 2 , and had a higher affinity for ERα. This correlates with previous studies that showed a slightly higher displacement of E 2 from ERα than from ERβ by P104 [30] . Despite binding to ERα with a higher affinity, P104 was not able to activate an ERE containing promoter reporter construct through ERα, but was able to do so through ERβ with an efficacy similar to that of E 2 , although its potency was much lower. In addition, P104 induced cell proliferation of MCF-7 cells, but it was less potent than E 2 . SM6Met has also been shown to bind to the ER by performing whole cell binding assays in MCF-7 cells. Unfortunately, these results cannot distinguish between binding to specific ER isoforms as MCF-7 cells contain both ERα and ERβ. Similar to P104, SM6Met also activated an ERE containing promoter reporter construct and induced cell proliferation in MCF-7 cells and like P104, SM6Met had a lower potency than E 2 in both assays. The extracts were analysed with HPLC, and l " Table 4 shows the polyphenols detected. Apart from these, the extracts were also screened for narirutin, eriodictyol, naringenin, hesperetin, and formononetin. Although these polyphenols were not present in quantifiable amounts, one cannot exclude the possibility of their presence and thus the effect they may have on the estrogenicity of the whole extract. The unidentified compounds in the extract of Mfenyana et al. [44] have since been tentatively identified (l " Table 4 ) as the flavone, scolymoside, and the dihydrochalcone, phloretin 3′,5′-di-C-β-glucoside. The presence of unidentified compounds was also previously indicated for P104 [32] , but they were not quantified. Comparison of l " Tables 3 and 4 may allow the deduction of which of the polyphenols might be causing the phytoestrogenicity of the extracts. Both extracts contain the xanthones mangiferin and isomangiferin, but as they are not phytoestrogenic [30, 32, 45] (l " Tables 2 and 3) , it is unlikely that they are contributing. Hesperidin also does not bind to hERα or hERβ and is un- Table 3 ). As glycosides are likely to be metabolised to their aglycones in vivo, hesperidin should not be discounted for in vivo studies, however, for in vitro testing, it is unlikely to contribute to the estrogenicity of the extracts. Luteolin has been shown to bind to both ER isoforms [30, 32, 37, 46] , to activate an ERE promoter reporter construct through both isoforms [32, 43, 46] , and to induce proliferation of a breast cancer cell line (l " Table 3 ). The amount of luteolin present was, however, shown to be too low to explain the degree of phytoestrogenicity observed for the P104 [32] or SM6Met [44] extract. On the other hand, scolymoside, the 7-O-rutinoside of luteolin, may be important in vivo. The flavanone eriocitrin was quantified in SM6Met, but not in P104 (l " Table 4 ). Eriocitrin has been shown to bind to ERβ [30] , but no further tests for estrogenicity have been performed (l " Table 3 ). To our knowledge, scolymoside and phloretin 3′,5′-di-C-β-glucoside tentatively identified in SM6Met have not been tested for phytoestrogenicity (l " Table  2 ). Taken together, no concrete conclusions regarding the polyphenols responsible for the phytoestrogenic effect of extracts of Cyclopia can be drawn. Some of the identified polyphenols still need to be tested for phytoestrogenicity, and the desired answer might be found in the results from these studies. We cannot, however, exclude the possibility that the effect seen with the Cyclopia extracts is the result of a fine balance between different polyphenols present in varying amounts with varying phytoestrogenic potential (agonistic, antagonistic, or SERM activity via either ERα or ERβ) and that synergism or antagonism could play a role with multiple polyphenols targeting multiple ER isoforms [47] .
Blanket Claims for Phytoestrogenic Potential of Cyclopia ! Caution should be exercised in making blanket claims for the phytoestrogenic potential of all harvestings of Cyclopia. Research indicates that variations in the polyphenol composition or content as well as the phytoestrogenic potential of individual harvestings of a specific Cyclopia species may differ (l " Table 5 ). For example, C. genistoides dried methanol extracts differed remarkably in their ability to induce cell proliferation in the E-screen assay with three out of the six harvestings displaying such low levels of activity that EC 50 values could not be determined (l " Table  5 ). Even amongst the harvestings with higher activity, there was considerable variation with M7 and NP105 extracts displaying 1.4-and 3.3-fold less activity than NP104. In addition, the concentration of luteolin, a polyphenol with proven phytoestrogenic potential (l " Table 3 ), also varied between harvestings with a 2.6fold difference between the harvesting with the highest concentration (M9) and that with the lowest concentration (NP104 or NP105) of luteolin (l " Table 5 ). This variability in polyphenol content is even more pronounced both quantitatively and qualitatively between species of Cyclopia with, for example, eriocitrin varying between undetectable in the C. genistoides aqueous extract to 0.47 % of the aqueous extract of unfermented C. subternata [8] .
The lack of standardisation, both in terms of levels of active substances and activity levels, of botanical and dietary supplements plagues the industry. Combined with little to no regulation by national bodies regulating drug use in most countries, this has led to contrary and inconsistent findings relating to health benefits, which has damaged the credibility of the industry [48] . Thus for claims of phytoestrogenic activity in Cyclopia, individual harvestings would have to be tested for activity until such time as a marker compound(s) shown to be related to activity can be identified. a Whole cell bindings were performed in COS-1 cells transfected with hERα or hERβ [32] and in MCF-7 cells that contain both hERα or hERβ [44] . b RBA or relative binding affinity is expressed relative to that of E 2 (100 %) and was calculated as follows: 100 × IC 50 (E 2 )/IC 50 (test compound). c Values represent an average of values from different extractions of the same plant material. d ERE promoter reporter assays were performed in COS-1 cells transfected with hERα or hERβ [32] or in T47D-KBluc cells that contain both hERα or hERβ [44] . e RII or relative induction index is expressed relative to that of E 2 (100%) and was calculated as follows: 100 × EC 50 Potential Usage of Phytoestrogens ! Estrogen plays an important role in the development of the female reproductive tract, secondary sex characteristics, and in reproductive behaviour [49] . However, estrogen also influences the growth of hormone-dependent cancers such as breast cancer [50] . Hormone replacement therapy (HRT), which includes estrogen combined with or without progesterone, is given to alleviate the symptoms of menopause, and advocates of HRT believe that it also confers long-term benefits regarding cardiovascular disease, bone preservation, and general well-being [51, 52] . Although the efficacy, superiority, and cost effectiveness of estrogen in the treatment of menopausal symptoms is accepted [53] , recent large randomised clinical trials [54, 55] and observational studies [56] on HRT have modified the risk/benefit perception. Specifically, increased risk of breast cancer and cardiovascular disease has raised concerns amongst the public [57] , and the Endocrine Society statement of 2010 now recommends use of HRT with the lowest effective dose and for the shortest duration possible [58] . The double-edged sword of estrogen has prompted the search for alternatives in the management of menopause, and phytoestrogens have been suggested as a viable alternative, due to their potential to modulate estrogen action [59, 60] . In addition, epidemiological studies suggest that Asian populations who consume 20-50 mg soy/day have fewer occurrences of hormone-dependent diseases, including menopausal symptoms, osteoporosis, and breast cancer and that this lower incidence is not due to under reporting or genotypic factors [53, [61] [62] [63] . Pharmacological validation of claimed health benefits for phytoestrogens has, however, only recently been undertaken and most work has focused on in vitro assays to establish biological activity while large, well-designed in vivo studies have lagged behind [64] . Molecular aspects of phytoestrogens that have been heralded as positive regarding health benefits include the fact that phytoestrogens generally have orders of magnitude lower potency than estrogen [53, 65] , display estrogen agonist activities in the presence of low levels of estradiol (post-menopausal) and antagonistic activity in the presence of high levels of estradiol (premenopausal) [48] , exhibit partial selectivity for ERβ, the ER isoform believed to attenuate the proliferative effect of ERα [66, 67] , and many act like SERMs, making them safer for breast and endometrial tissue [29, 48, 68] . Furthermore, phytoestrogens have additional diverse beneficial biological effects, such as antiinflammatory, antioxidant, and anticancer effects [65, 69] . Several studies and reviews have evaluated the health potential of phytoestrogens for treating post-menopausal symptoms by maintaining bone density, decreasing cardiovascular disease and hot flashes, and in preventing or treating estrogen-dependent cancers such as breast, prostate, endometrial, and colon cancer [29, 48, 53, [70] [71] [72] [73] . Although there is contradictory scientific proof of the effectiveness of phytoestrogens, specifically soy and red clover isoflavones, for the treatment of vasomotor menopausal symptoms, such as hot flushes [29, 73, 74] , for other symptoms, such as osteoporosis and cardiovascular disease, the data to date strongly suggests efficacy. Specifically, phytoestrogens, such as coumestrol, genistein, daidzein and its metabolite equol as well as extracts from soy, black cohosh, and red clover, appear to slow bone loss and improve bone density [29, 48] , which is positive for osteoporosis, while for cardiovascular disease, phytoestrogens, primarily from soy, are beneficial in decreasing LDL and triglycerides, while increasing HDL [48, 53] . In addition, several studies have suggested that phytoestrogen use, mainly flavones and isoflavones from soy, is associated with a reduced risk of breast cancer [67, [75] [76] [77] . Despite beneficial effects of phytoestrogens being reported, results have, however, not always been favourable or reproducible [73] . For example, although some studies suggest that soy food intake does correlate with reduced risk or recurrence of breast cancer [78, 79] , other studies have found no such association between isoflavone intake and breast cancer risk [80, 81] . The diversity in results may be attributed to, amongst others, the fact that a wide variety and doses of botanicals have been used and the fact that standardisation of formulations are not currently required making comparison between studies difficult [29, 48, 70] . In addition, an evaluation of effects of phytoestrogenic preparations on health is complicated by the fact that exact formulations and concentrations of active constituents are not always known and studies are often retrospective (relying on recall of diet). Furthermore, the fact that there has never been a study comparable in size to the Million Womenʼs or WHI studies investigating side effects of phytoestrogen use should encourage caution. This is especially relevant as many consumers base their beliefs of both efficacy and safety on source rather than evidence [29] . Despite this caveat, there is no current data suggesting that dietary phytoestrogens promote hormone-dependent cancers in humans, and thus phytoestrogens can probably be used safely on a long-term basis [53, 73] . Finally, the fact that phytoestrogens are often not selected for specific attributes, such as acting only via ERβ, may have confounded studies on health effects. Some promising results regarding amelioration of hot flushes with liquiritigenin, an ERβ-selective agonist from a Chinese herbal extract, have, however, resulted in Phase 2 clinical trials to evaluate safety and efficacy for the treatment of menopausal symptoms [82, 83] . [44] ; b data from [32] ; c RII (relative induction index) = EC 50 E 2 /EC 50 extract; d ND = RII could not be determined as activity was too low
Conclusions !
The increased public and industry interest in phytoestrogens suggests that validated health claims would contribute significantly to adding value to products such as honeybush tea. Certain extracts of Cyclopia undoubtedly display estrogenic activity (l " Table 4 ), and many of the major and minor polyphenols found in Cyclopia certainly have been shown to have phytoestrogenic potential (l " Table 3 ), but whether this translates into firm health recommendations for a "cup-of-tea" of honeybush is debatable. Firstly, harvestings of Cyclopia differ significantly in terms of estrogenic activity and polyphenol content (l " Table 5 ), and secondly, Cyclopia extracts have not been tested for estrogenicity in vivo. The importance of evaluating the bioavailability as well as the metabolic transformation of active compounds, both by gut microflora and hepatic enzymes, has been stressed [31, 84] . Cyclopia extracts have been tested in vivo for absorption and metabolism [85, 86] ; however, the focus was on mangiferin and hesperidin, both compounds without estrogenic activity (l " Table 3 ).
The aglycone of hesperidin, hesperetin, which does display weak estrogenic activity, was, however, one of the metabolites detected in urine [85] . This suggests that glycosylated polyphenols, of which several constitute the major polyphenols in Cyclopia extracts (l " Table 1 ), would probably be transformed to the corresponding aglycone with higher phytoestrogenic activity. Finally, the concept of either synergistic or even antagonistic formulations consisting of intelligent mixtures of natural products to treat disease is gaining ground [47, [87] [88] [89] [90] [91] and thus, although we have focussed on the phytoestrogenicity of individual compounds found in Cyclopia, we should consider the possibility that it is the mixture of compounds found in Cyclopia extracts, rather than an individual compound, that confers the desired estrogenic activity.
